Quantcast

Industry news that matters to you.  Learn more

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

Invivoscribe® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics®, and personalized molecular medicine®, reports that its next-generation sequencing (NGS) LymphoTrack® Assay kits are being used by its LabPMM® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T-cells (CAR-T) and engineered T-cell receptors in peripheral blood of subjects in support of immuno-therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

Scientists Discover Why Some Cancers May Not Respond to Immunotherapy

UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or no benefit from the immunotherapy drug pembrolizumab. This early-stage research has allowed them to determine for the first time why some people with advanced melanoma or advanced colon cancer will not respond to pembrolizumab, an anti-PD-1 treatment.

HIV Discovery — Biomarkers Predict Virus Return When Treatment is Stopped

Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford.

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

The University of Pennsylvania recently reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia. The CACT will become the epicenter for research using Chimeric Antigen Receptor technology (CAR), which enables a patient’s T cells to be reprogrammed outside of the body so when they are re-infused into the patient, the T cells have the ability to “hunt” and destroy the cancer cells. Clinical trials using this approach have made headlines around the world.

ImaginAb Enters into Exclusive Licensing Agreement with UCLA for Immune Cell Imaging Agents

ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement, ImaginAb gains exclusive access to novel imaging agents that target specific markers of murine T-cells, enabling a new understanding of response to immunotherapeutic drugs in pre-clinical models.